The most codified market in the world.
Free pricing on day one, a statutory verdict at month six, and guardrails that turn the rating into a price corridor.
55% of 1,039 resolutions: no added benefit provenThe market where the model is the product.
Cost per QALY at the centre of the decision, a 90-day funding mandate behind a yes, and one appraisal in five ending terminated.
92% of decided appraisals positive · 61% restrictedTwo grades decide everything.
SMR decides whether the state pays; ASMR decides what price you can ask. Four in five dossiers are told they bring nothing new.
81% of ASMR ratings ever given: "no improvement"The market where "no" means "not yet".
A thrice-yearly assessment cycle, reference pricing at the core, and the most openly iterative rejection culture of any major payer.
42% of rejected molecules eventually recommendedSmall market, separate answer.
Submission-driven, fast, and unforgiving of silence: no submission is scored as a no, and resubmission is the normal second act.
80% of decided full submissions acceptedEach pathway covers the institutions and their roles, the evidence each gate actually weighs, the statutory clocks, and the places companies predictably get hurt. Written for teams planning a launch without a standing market access function. The empirical numbers come from our own five-agency decision database, refreshed continuously, so every claim is checkable.
Launching into any of these markets?
The pathways are the map. We build the vehicle: evidence strategy, payer-ready models and pricing corridors for the specific gates your asset faces. Fixed fees, senior-built.
Talk to us about your launch